Literature DB >> 11875313

Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells.

Takahiro Shiokoshi1, Yoshinobu Ohsaki, Junichi Kawabe, Takayuki Fujino, Kenjiro Kikuchi.   

Abstract

BACKGROUND: Cytokines from inflammatory cells do not produce nitric oxide, but stimulate the production of nitric oxide in vascular smooth muscle cells (VSMC). Thromboxane A2 (TXA2) has been believed to have a key role in atherosclerogenesis and post-angioplasty restenosis.
OBJECTIVE: To determine whether cytokine-induced nitric oxide production is regulated by the TXA2/prostaglandin H2 (PGH2) receptor. METHODS AND
RESULTS: We studied the interleukin-1beta (IL-1beta)-induced production of nitric oxide in rat VSMCs using the TXA2/PGH2 receptor antagonists, seratrodast and Bay-u3405, and an agonist, U-46619. Nitrite formation was measured colorimetrically. IL-1beta increased nitrite formation in a time-dependent manner. The nitrite concentration was 1.7 times greater in the presence of seratrodast than that without it. Nitrite accumulation was increased by Bay-u3405, but was decreased in the presence of U-46619, to 44% of that in its absence. Western and Northern blotting showed that seratrodast increased the levels of expression of inducible nitric oxide synthase (iNOS) protein and mRNA in a dose-dependent manner, whereas U-46619 decreased them. We speculated that VSMCs produced TXA2, thereby decreasing nitric oxide production; therefore we measured the accumulation of TXB2 using an enzyme immunoassay. Untreated VSMCs produced about 20 pg/mg protein of TXB2. This was increased by the addition of IL-1beta, to 152.1 +/- 43.0 pg/mg protein after a 24 h incubation; the expression of cyclooxygenase-2 (COX-2) protein was also increased, but there was no effect on the expression of COX-1 and TXA2 synthase. U-63557A, a TXA2 synthase inhibitor, increased the accumulation of nitrite to 1.3-fold that in its absence.
CONCLUSIONS: These data suggest that the expression of iNOS and the production of nitric oxide are regulated by the TXA2/PGH2 receptor in IL-1beta-stimulated VSMCs. The endogenous production of TXA2 by the induction of COX-2 from IL-1beta-stimulated VSMCs probably downregulated the production of nitric oxide in VSMCs. TXA2/PGH2 receptor inhibitors may contribute to the reduction in formation of atherosclerosis in lesions with vascular injury by enhancing the production of nitric oxide by VSMCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875313     DOI: 10.1097/00004872-200203000-00021

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

1.  The role of inflammation and COX-derived prostanoids in the effects of bradykinin on isolated rat aorta and urinary bladder.

Authors:  Kevser Erol; Basar Sirmagul; Fatma Sultan Kilic; Semra Yigitaslan; Ali Evrim Dogan
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

2.  Cyclooxygenase-2 and inducible nitric oxide synthase in omental arteries harvested from patients with severe liver diseases: immuno-localization and influence on vascular tone.

Authors:  Antonia Tabernero; Francis Schneider; Maria Assunta Potenza; Voahanginirina Randriamboavonjy; Sylvette Chasserot; Philippe Wolf; Delia Mitolo-Chieppa; Jean-Claude Stoclet; Ramaroson Andriantsitohaina
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

3.  In the presence of L-NAME SERCA blockade induces endothelium-dependent contraction of mouse aorta through activation of smooth muscle prostaglandin H2/thromboxane A2 receptors.

Authors:  Elena B Okon; Ali Golbabaie; Cornelis van Breemen
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

4.  Increased cyclooxygenase-2-derived prostanoids contributes to the hyperreactivity to noradrenaline in mesenteric resistance arteries from offspring of diabetic rats.

Authors:  Fernanda E Ramos-Alves; Diego B de Queiroz; Juliana Santos-Rocha; Gloria P Duarte; Fabiano E Xavier
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.